visterra inc
Engineered Antibody Neutralizes All Four Dengue Serotypes
Researchers have designed an antibody that targets all four serotypes of dengue, sparking hopes for the first viable dengue therapeutic.
Visterra & A*STAR To Bring Dengue Antibody To Clinical Trials
A*STAR's D3 has joined Visterra to bring the dengue monoclonal antibody VIS513 to proof-of-concept clinical trials.